Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned approval application. The company had been evaluating ersodetug as a treatment ...

Northrop Grumman test-fired a solid rocket motor called SMASH!22 Dec. 4 as part of its SMART Demo development program. Credit: Northrop Grumman WASHINGTON — Northrop Grumman tested a solid rocket ...

Watch old broken electric motors transformed into flawless copper ingots! From wire extraction and melting to casting and forging, see the full recycling process in action. Where immigrants went ...

A Nothing Phone 3 retail demo was spotted making misleading claims about photo samples. Android Authority has spoken to two of the photographers who shot the pics, who confirm they did not use the ...

In this video, we focus on recycling copper from old broken electric motors into usable materials. The process includes extracting copper wires, melting the copper, casting ingots, forging them to ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though analysts pledged to wait for more data on safety and tolerability before assessing ...

Google is rolling out Veo 3 to everyone using Vertex AI, which is an ML-testing platform provided by Google Cloud. Unlike Sora and other generative video AI models, Veo 3 is a state-of-the-art video ...

HELSINKI — Chinese launch startup Landspace carried out a breakthrough static fire test Friday as it builds towards an orbital launch attempt with its Zhuque-3 rocket. The nine engines of the Zhuque-3 ...

Scientists at the Korea Institute of Science and Technology (KIST) have developed a new class of lightweight, highly conductive carbon nanotube (CNT) wiring that does away with copper and aluminum ...

Google is now giving AI Pro subscribers in the Gemini app more video generations with Veo 3 Fast after previously providing a 10-pack trial. Veo 3 is Google’s latest model for video with the ability ...

A Johnson & Johnson gene therapy in development for an inherited vision-loss disorder has failed a Phase 3 study, the latest clinical research setback for a rare eye disease that so far has no ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomized, ...